Highlights•Traditional drug screening model systems are inadequate.•Organoid-on-a-chip
platforms stand to significantly advance drug and toxicology screening.•A wide variety or …

The complex interaction of cells with biomaterials (ie, materiobiology) plays an increasingly
pivotal role in the development of novel implants, biomedical devices, and tissue …

Organ-on-a-chip systems are miniaturized microfluidic 3D human tissue and organ models
designed to recapitulate the important biological and physiological parameters of their in …

Engineering cardiac tissues and organ models remains a great challenge due to the
hierarchical structure of the native myocardium. The need of integrating blood vessels brings …

To curb the high cost of drug development, there is an urgent need to develop more
predictive tissue models using human cells to determine drug efficacy and safety in advance …

Many drugs have progressed through preclinical and clinical trials and have been available–
for years in some cases–before being recalled by the FDA for unanticipated toxicity in …

Cardiovascular disease is the leading cause of death worldwide. Although investment in
drug discovery and development has been sky-rocketing, the number of approved drugs has …

Abstract Organ‐on‐a‐chip (OOC) platforms recapitulate human in vivo‐like conditions more
realistically compared to many animal models and conventional two‐dimensional cell …

Continual monitoring of secreted biomarkers from organ-on-a-chip models is desired to
understand their responses to drug exposure in a noninvasive manner. To achieve this goal …

There is a growing interest to develop microfluidic bioreactors and organ-on-chip platforms
with integrated sensors to monitor their physicochemical properties and to maintain a well …